Effects of gait training with a voluntary driven Wearable Cyborg, Hybrid Assistive Limb (HAL), in patients with spinal cord disease

Effects of gait training with a voluntary driven Wearable Cyborg, Hybrid Assistive Limb (HAL), in patients with spinal cord disease - Treatment with Hybrid Assistive Limb (HAL), in patients with spinal cord disease

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000041280

Enrollment

Registered

2020-08-03

Start date

2020-07-31

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

spinal cord disease

Interventions

In group A, walking rehabilitation using HAL is performed for 3 months, and then conventional walking rehabilitation centered on assisted walking training by a therapist is performed for 3 months. In

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: More than 6 months have passed since the onset of spinal cord disease or surgical treatment. Lower limb dysfunction due to spinal cord disease remains, resulting in a decline in walking ability. As for spinal cord injury, ASIA dysfunction scales C and D are used. It is possible to walk for 10 meters or more without support or using a walking aid.

Exclusion criteria

Exclusion criteria: Other central nervous system diseases, nerve/muscle diseases, or locomotor system diseases clearly influence the deterioration of walking ability. HAL is difficult to wear due to severe deformation of limbs and trunk caused by osteoarthritis, spondylosis, scoliosis, etc. It is difficult to follow the instructions due to severe dementia. Has respiratory, circulatory, and metabolic system dysfunction, bleeding tendency, and osteoporosis, which are problems in training. Biomedical electrodes cannot be attached due to skin diseases.

Design outcomes

Primary

Measure	Time frame
The parameters were measured before treatment, 3 month after treatment. 1. JOA score 2. ADL score(Barthel index,Functional Independence Measure) 3. Patient-standing QOL score(SF36,EuroQOL-5D) 4. 10-m walk test 5. 6-min walk test 6. Tilt of the trunk and angle of hips, knees and ankles during walking 7. Lower extremity muscle activity during walking (gluteus maximus, gluteus medius, quadriceps, hamstring, tibialis anterior, triceps surae) 8. Signal intensity of nerve conduction path in simple MRI images (Synthetic MRI, Quantitative Susceptibility Mapping, diffusion tensor image, 3D-MRI, 3D-FLAIR, Finger-Printing)	—

Measure

Time frame

The parameters were measured before treatment, 3 month after treatment. 1. JOA score 2. ADL score(Barthel index,Functional Independence Measure) 3. Patient-standing QOL score(SF36,EuroQOL-5D) 4. 10-m walk test 5. 6-min walk test 6. Tilt of the trunk and angle of hips, knees and ankles during walking 7. Lower extremity muscle activity during walking (gluteus maximus, gluteus medius, quadriceps, hamstring, tibialis anterior, triceps surae) 8. Signal intensity of nerve conduction path in simple MRI images (Synthetic MRI, Quantitative Susceptibility Mapping, diffusion tensor image, 3D-MRI, 3D-FLAIR, Finger-Printing)

—

Countries

Japan

Contacts

Public ContactEiichi Tsuda

Hirosaki University, Graduate School of Medicine Dept. of Rehabilitation Medicine

eiichi@hirosaki-u.ac.jp0172-33-5111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026